GlassScriptPhysician profile
Robert Kevin Smith
NPI 1891773578
$236.58
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.28 · 2020: $123 · 2021: $69.47.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $41.38 | 2019-2020 | |
| Organon LLC | $33.43 | 2021 | |
| Abbvie INC. | $32.70 | 2020 | |
| Merck Sharp & Dohme LLC | $31.95 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $19.69 | 2021 | |
| Amgen INC. | $17.44 | 2020 | |
| Myovant Sciences INC. | $16.35 | 2021 | |
| Vertical Pharmaceuticals, LLC | $16.07 | 2020 | |
| Avion Pharmaceuticals | $15.05 | 2020 | |
| Amag Pharmaceuticals, INC. | $12.52 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.